Cellular Goods PLC Grant of Warrants (1766C)
09 June 2023 - 04:00PM
UK Regulatory (RNS & others)
TIDMCBX
RNS Number : 1766C
Cellular Goods PLC
09 June 2023
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014, as retained as part of
the law of England and Wales. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
Press release
9 June 2023
Cellular Goods PLC
("Cellular Goods" or "the Company")
Grant of Warrants
Cellular Goods (LSE: CBX) a UK-based skincare and wellness
company providing premium consumer products formulated with
lab-produced cannabinoids, announces that it has granted a total of
3,000,000 warrants to subscribe for new ordinary shares of GBP0.001
each ("Warrants") to members of its Advisory Board. The Warrants
are exercisable at 1.5 pence per ordinary share.
One third of the warrants will vest on 8 June 2024 with the
remaining two thirds vesting in 24 equal monthly instalments
thereafter. The Warrants have an exercise period from the date of
grant to 8 June 2028.
Following the issue of the Warrants, the Company has a total of
12,500,000 warrants in issue.
For further information please contact:
Cellular Goods
Darcy Taylor via Tancredi +44 207 887 7633
Chairman and interim CEO
Neil Thapar +44 787 645 5323
Investor Relations
------------------------------
First Sentinel Corporate Finance
------------------------------
Corporate Broker & Advisor
Brian Stockbridge +44 7876 888 011
------------------------------
Novum Securities
------------------------------
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Helen Humphrey
Charlie Hobbs +44 744 922 6720
cellulargoods@tancredigroup.com +44 789 755 7112
------------------------------
About Cellular Goods PLC:
Cellular Goods develops and markets premium quality skincare and
wellness products based on proprietary formulations incorporating
biosynthetic lab-made cannabinoids. Our branded products are
efficacy-led and research-backed and available online in the UK and
US. The Company is incorporated in the UK and listed on the Main
Market of the London Stock Exchange. For more information, visit
www.cellular-goods.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEVVLFBXQLLBBL
(END) Dow Jones Newswires
June 09, 2023 02:00 ET (06:00 GMT)
Cellular Goods (LSE:CBX)
Historical Stock Chart
From Nov 2023 to Dec 2023
Cellular Goods (LSE:CBX)
Historical Stock Chart
From Dec 2022 to Dec 2023